BioCryst Pharmaceuticals, Inc.
BCRX
$10.34
$0.505.08%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -384.67M | -457.98M | 263.86M | -8.78M | -35.71M |
| Total Depreciation and Amortization | 4.40M | 4.22M | 3.49M | 3.43M | 3.05M |
| Total Amortization of Deferred Charges | 352.00K | 608.00K | 1.00M | 1.00M | 1.00M |
| Total Other Non-Cash Items | 827.71M | 832.42M | 135.92M | 127.00M | 128.70M |
| Change in Net Operating Assets | -71.66M | -66.17M | -56.90M | -72.46M | -80.22M |
| Cash from Operations | 376.14M | 313.10M | 347.37M | 50.20M | 16.82M |
| Capital Expenditure | -2.76M | -2.73M | -2.47M | -2.34M | -1.06M |
| Sale of Property, Plant, and Equipment | 550.00K | 550.00K | 550.00K | 550.00K | -- |
| Cash Acquisitions | -489.48M | -489.48M | -- | -- | -- |
| Divestitures | -6.18M | -6.18M | -6.18M | -- | -- |
| Other Investing Activities | 49.16M | 188.40M | -5.59M | 89.38M | 83.56M |
| Cash from Investing | -448.71M | -309.44M | -13.69M | 87.59M | 82.51M |
| Total Debt Issued | 400.00M | 400.00M | -- | -- | -- |
| Total Debt Repaid | -272.52M | -335.06M | -334.76M | -137.98M | -77.68M |
| Issuance of Common Stock | 29.11M | 26.29M | 9.17M | 8.49M | 7.92M |
| Repurchase of Common Stock | -11.51M | -8.68M | -8.85M | -6.51M | -6.14M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -20.45M | -20.45M | -15.50M | -- | -- |
| Cash from Financing | 124.63M | 62.09M | -349.93M | -135.99M | -75.90M |
| Foreign Exchange rate Adjustments | -647.00K | 747.00K | 1.27M | 38.00K | 1.36M |
| Miscellaneous Cash Flow Adjustments | 15.06M | 0.00 | 0.00 | -14.84M | -15.06M |
| Net Change in Cash | 66.46M | 66.50M | -14.99M | -13.01M | 9.72M |